Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04801914
Other study ID # 717/11
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 11, 2020
Est. completion date May 11, 2021

Study information

Verified date March 2021
Source Institut za Rehabilitaciju Sokobanjska Beograd
Contact Aleksandar N Filipovic, Dr
Phone +381658832505
Email aleksandar.filipovic11@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to detect differences in the enzymatic activity of matrix metalloproteinases in patients with malignant obstructive hyperbilirubinemia before and after percutaneous biliary drainage.


Description:

This study will be designed as a prospective cohort study involving the collection of peripheral blood samples before and one month after percutaneous biliary drainage for further molecular biochemical analysis (measurement of serum matrix metalloproteinase activity). Biochemical analyzes are preceded by the entry of data relevant to the research (demographic, anamnestic, clinical and biochemical).


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date May 11, 2021
Est. primary completion date March 11, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: pathological confirmation or imaging data confirming malignant disease causing bile duct obstruction, performance status 0-1 Exclusion Criteria: terminally ill patients, performance status >2, hepatic decompensation, severe underlying cardiac or renal diseases and coagulation disorders.

Study Design


Intervention

Procedure:
Percutaneous biliary drainage
Collection of peripheral blood samples before and one month after percutaneous biliary drainage performed for patients with malignant obstructive hyperbilirubinemia for further molecular biochemical analysis (measurement of serum matrix metalloproteinase activity).

Locations

Country Name City State
Serbia University Clinical Center of Serbia Belgrade

Sponsors (2)

Lead Sponsor Collaborator
Institut za Rehabilitaciju Sokobanjska Beograd Klinicki centar Srbije

Country where clinical trial is conducted

Serbia, 

Outcome

Type Measure Description Time frame Safety issue
Primary MMP-2 and MMP-9 serum activity MMP serume activity will be measured by molecular biochemical analysis performed on peripheral blood samples taken before and one month after percutaneous biliary drainage during intervention